US4632919A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for prolonging recalcification, prothrombin and thrombin times of plasma
Assignee: N J, University of, Medicine and Dentistry of
•
Filing: 1984-09-27
•
Granted: 1986-12-30
•
Expires: 2004-09-27
Abstract
Abstract There is disclosed a process for prolonging recalcification, prothrombin and thrombin times of human plasma which comprises administering to a warm-blooded animal a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.
Inventors
- 👤 Charles R. Spillert
- 👤 Corinne Devereux
- 👤 Eric J. Lazaro
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 08:38
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/63; A61K31/635; A61K31/33; A61K31/395; A61K31/495; A61K31/505
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
99 words
A process for treating a warm-blooded animal to prolong at least one of recalcification, prothrombin or thrombin time of plasma which comprises administering to a warm-blood animal in need of such treatment (a) at least one member selected from the group consisting of 5-methyl-3-sulfanil-amidoisoxazole and a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base and (b) at least one member selected from the group consisting of 2,4,-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine and a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine with a pharmaceutically acceptable acid, said components (a) and (b) being administered in an amount effective to prolong at least one of recalcification, prothrombin or thrombin time.
Claim 2
Dependent Claim
99 words
A process for treating a warm-blooded animal to prolong at least one of recalcification, prothrombin or thrombin time of plasma which comprises administering to a warm-blood animal in need of such treatment (a) at least one member selected from the group consisting of 5-methyl-3-sulfanil-amidoisoxazole and a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base and (b) at least one member selected from the group consisting of 2,4,-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine and a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine with a pharmaceutically acceptable acid, said components (a) and (b) being administered in an amount effective to prolong at least one of recalcification, prothrombin or thrombin time.
Claim 3
Dependent Claim
56 words
The process as defined in claim 1 wherein said therapeutically effective amount of the composition comprises from about 250 mg. to about 800 mg. of 5-methyl-3-sulfanilamidoisoxazole or an alkali metal salt thereof with a pharmaceutically acceptable base and from about 12.5 mg. to 160 mg. of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine or a salt thereof with a pharmaceutically acceptable acid.
Claim 4
Dependent Claim
41 words
The process as defined in claim 1 wherein a component level in the plasma of the warm-blooded animal of said 5-methyl-3-sulfanilamidoisoxazole or an alkali metal salt thereof with a pharmaceutically acceptable base is maintained at from about 80 to 160 μg./cc.
Claim 5
Dependent Claim
16 words
The process as defined in claim 3 wherein said component level is preferably about 110 μg./cc.
Claim 6
Dependent Claim
39 words
The process as defined in claim 1 wherein a component level in the plasma of the warm-blooded animal of said 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine or a salt thereof with a pharmaceutically acceptable acid is maintained at from about 5 to 15 μg./cc.
Claim 7
Dependent Claim
16 words
The process as defined in claim 5 wherein said component level is preferably about 10 μg./cc.
Claim 8
Dependent Claim
13 words
The process of claim 1 wherein components (a) and (b) are administered separately.
Claim 9
Dependent Claim
13 words
The process of claim 1 wherein components (a) and (b) are administered together.
References Cited (Backward Citations)
US3985876A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-12-29 | 1990-06-30 | 1990-12-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-12-29 | 1994-06-30 | 1994-12-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-12-29 | 1998-06-30 | 1998-12-30 | $7700.00 | Window Closed / Lapsed |